<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585999</url>
  </required_header>
  <id_info>
    <org_study_id>H-34252</org_study_id>
    <nct_id>NCT02585999</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of 12 Week Continuous Patch Use</brief_title>
  <official_title>The Pharmacokinetics of 12 Week Continuous Patch Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of
      estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The
      primary objective is to assess the change in serum ethinyl estradiol (EE2) levels over 12
      weeks of continuous contraceptive patch use. The secondary objective is assessing the the
      norelgestromin (NGMN) levels over the 12 weeks of continuous contraceptive patch use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For women who are seeking alternatives to long-acting contraceptives, the oral contraceptive
      pill and the contraceptive ring are often prescribed in an extended manner (12 weeks
      straight). The contraceptive patch, however, is not routinely prescribed in this way.
      Concerns have been raised that hormone levels, in particular estrogen, are higher among patch
      users than those who use oral contraception or the vaginal ring and that this may contribute
      to an increased risk of clot. However, few studies have actually looked at these hormone
      levels in women with extended use of the contraceptive patch.

      The investigators plan to enroll eligible women age 18-39 who are willing to use the
      contraceptive patch continuously for twelve weeks, and can adhere to the study requirements
      for follow-up. All participants will have weekly serum assessments of ethinyl estradiol and
      norelgestromin levels. The investigators will enroll 30 women, in anticipation of a 33%
      attrition rate, with the goal of obtaining completed data on 20 participants. The study
      duration for an individual participant will be 12 weeks and the duration of the entire study
      will be one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use</measure>
    <time_frame>Total of 18 blood draws - once at the end of each patch week and two times during weeks four, eight and twelve (with the additional blood draw occurring mid-week); and blood draws performed for three continuous days after the final patch was removed</time_frame>
    <description>Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess EE2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NGMN Levels Over 12 Weeks of Continuous Patch Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess NGMN</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Xulane</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants using the Xulane contraceptive patch for 12 continuous weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xulane Contraceptive Patch</intervention_name>
    <description>Extended use (12 weeks) of contraceptive patch</description>
    <arm_group_label>Xulane</arm_group_label>
    <other_name>Ortho Evra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to come to the clinic to have blood drawn weekly for 12 weeks,
             biweekly during weeks 4, 8, and 12, and for 3 days after the final patch is removed
             for blood draws for a total of 18 blood draws

          -  Willing and able to abstain from using any other hormonal contraceptive method while
             in the study and for the week prior to starting the study

        Exclusion Criteria:

          -  Body Mass Index greater than 35

          -  Personal or Family History of Venothromboembolism

          -  Personal History of Migraines with Aura

          -  Personal History of Migraines without Aura

          -  Tobacco use greater than or equal to 15 cigarettes per day

          -  Current Pregnancy

          -  History of or Current Diagnosis of Cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonella Lavelanet, DO, JD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <results_first_submitted>June 30, 2016</results_first_submitted>
  <results_first_submitted_qc>April 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Antonella Lavelanet</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Hormonal contraception, hormone pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Ortho Evra</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>30 participants completed the baseline questionnaire, but 2 withdrew prior to starting the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xulane</title>
          <description>Participants exposed to contraceptive patch, Xulane.
Xulane Contraceptive Patch (generic version of Ortho Evra®*): Extended use (12 Weeks) of Contraceptive Patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">28 participants enrolled; 2 withdrew prior to starting, leaving 26 to complete study activity.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>30 participants completed the baseline questionnaire, but 2 withdrew prior to starting the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Xulane</title>
          <description>Participants exposed to contraceptive patch, Xulane.
Xulane Contraceptive Patch (generic version of Ortho Evra®*): Extended use (12 Weeks) of Contraceptive Patch</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use</title>
        <description>Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess EE2</description>
        <time_frame>Total of 18 blood draws - once at the end of each patch week and two times during weeks four, eight and twelve (with the additional blood draw occurring mid-week); and blood draws performed for three continuous days after the final patch was removed</time_frame>
        <population>Analysis was performed on all samples. Thus samples for 28 participants were analyzed, including the one participant who began the study but withdrew early [lost to follow up]. The first blood draw occurred at the end of the first patch week; there was no baseline draw prior to patch use.</population>
        <group_list>
          <group group_id="O1">
            <title>Xulane</title>
            <description>Participants exposed to Xulane Contraceptive Patch for 12 weeks of continuous use</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use</title>
          <description>Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess EE2</description>
          <population>Analysis was performed on all samples. Thus samples for 28 participants were analyzed, including the one participant who began the study but withdrew early [lost to follow up]. The first blood draw occurred at the end of the first patch week; there was no baseline draw prior to patch use.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3.5 (mid-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7.5 (mid-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11.5 (mid-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12.1 (day 1 post patch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12.2 (day 2 post patch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12.3 (day 3 post patch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NGMN Levels Over 12 Weeks of Continuous Patch Use</title>
        <description>Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess NGMN</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis was performed on all samples. Thus samples for 28 participants were analyzed, including the one participant who began the study but withdrew early [lost to follow up]. The first blood draw occurred at the end of the first patch week; there was no baseline draw prior to patch use.</population>
        <group_list>
          <group group_id="O1">
            <title>Xulane</title>
            <description>All participants using the Xulane contraceptive patch for 12 continuous weeks
Xulane Contraceptive Patch: Extended use (12 weeks) of contraceptive patch</description>
          </group>
        </group_list>
        <measure>
          <title>NGMN Levels Over 12 Weeks of Continuous Patch Use</title>
          <description>Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess NGMN</description>
          <population>Analysis was performed on all samples. Thus samples for 28 participants were analyzed, including the one participant who began the study but withdrew early [lost to follow up]. The first blood draw occurred at the end of the first patch week; there was no baseline draw prior to patch use.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.691" spread="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.699" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.674" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3.5 (mid-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.746" spread="0.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.877" spread="0.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.913" spread="0.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.689" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7.5 (mid-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.789" spread="0.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.814" spread="0.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.837" spread="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.792" spread="0.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11.5 (mid-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.954" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.593" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12.1 (day 1 post patch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.422" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12.2 (day 2 post patch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.221" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12.3 (day 3 post patch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.163" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the entire course of the study (October 2015 through June 2016).</time_frame>
      <desc>The at risk numbers represent the 28 participants who were enrolled in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Xulane</title>
          <description>All participants using the Xulane contraceptive patch for 12 continuous weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It is difficult to compare our findings with those of previous studies, as previous studies have used other instrumentation and techniques in analysis of EE2. Serum analysis was also performed after all samples were collected from participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Antonella Lavelanet</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>6174143745</phone>
      <email>Katharine.White@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

